GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer

• JEMAL A, SIEGEL R, WARD E et al.: Cancer statistics, 2007. CA Cancer J. Clin. (2007) 57(1):43-66.
   PubMed Web of Science ®Google Scholar
• KIRK TN, MOYAD MA: National survey of advanced prostate cancer patients reveals disparity between perceptions and reality of treatment. Proc. Am. Soc. Clin. Oncol. (2006) 24(S490):Abstract 8590.
   Google Scholar
• MCNEEL DG: Prostate cancer immunotherapy. Curr. Opin. Urol. (2007) 17(3):175-181.
   PubMed Web of Science ®Google Scholar
• KIPP RT, MCNEEL DG: Immunotherapy for prostate cancer – recent progress in clinical trials. Clin. Adv. Hematol. Oncol. (2007) 5(6):465-474, 477-479.
   PubMedGoogle Scholar
• EHRLICH P: Immunology and cancer research. In: The Collected Papers of Paul Erlich (Volume 2). Himmelwiet F (Ed.), Pergamon Press, London, UK (1957):7-472.
   Google Scholar
• EHRLICH P: über den jetzigen Stand der Karzinomforschung. Ned Tijdschr Geneeskd (1909) 5:273-290.
   Google Scholar
• PREHN RT, MAIN JM: Immunity to methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst. (1957) 18(6):769-778.
   PubMed Web of Science ®Google Scholar
• DRANOFF G, JAFFEE E, LAZENBY A et al.: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA (1993) 90(8):3539-3543.
   PubMed Web of Science ®Google Scholar
• SANDA MG, AYYAGARI SR, JAFFEE EM et al.: Demonstration of a rational strategy for human prostate cancer gene therapy. J. Urol. (1994) 151(3):622-628.
   PubMed Web of Science ®Google Scholar
• VIEWEG J, ROSENTHAL FM, BANNERJI R et al.: Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res. (1994) 54(7):1760-1765.
   PubMed Web of Science ®Google Scholar
• BERARD F, BLANCO P, DAVOUST J et al.: Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J. Exp. Med. (2000) 192(11):1535-1544.
   PubMed Web of Science ®Google Scholar
• HUANG AY, GOLUMBEK P, AHMADZADEH M et al.: Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (1994) 264(5161):961-965.
   PubMed Web of Science ®Google Scholar
• KURBACHER CM, KURBACHER JA, CRAMER EM et al.: Continuous low-dose GM-CSF as salvage therapy in refractory recurrent breast or female genital tract carcinoma. Oncology (2005) 19(4 Suppl. 2):23-26.
   PubMed Web of Science ®Google Scholar
• ROKHLIN OW, GRIEBLING TL, KARASSINA NV et al.: Human prostate carcinoma cell lines secrete GM-CSF and express GM-CSF-receptor on their cell surface. Anticancer Res. (1996) 16(2):557-563.
   PubMed Web of Science ®Google Scholar
• RIVAS CI, VERA JC, DELGADO-LOPEZ F et al.: Expression of granulocyte-macrophage colony-stimulating factor receptors in human prostate cancer. Blood (1998) 91(3):1037-1043.
   PubMed Web of Science ®Google Scholar
• SAVARESE DM, VALINSKI H, QUESENBERRY P et al.: Expression and function of colony-stimulating factors and their receptors in human prostate carcinoma cell lines. Prostate (1998) 34(2):80-91.
   PubMed Web of Science ®Google Scholar
• SMALL EJ, REESE DM, UM B et al.: Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin. Cancer Res. (1999) 5(7):1738-1744.
   PubMed Web of Science ®Google Scholar
• DREICER R, SEE WA, KLEIN EA: Phase II trial of GM-CSF in advanced prostate cancer. Invest. New Drugs (2001) 19(3):261-265.
   PubMed Web of Science ®Google Scholar
• RINI BI, WEINBERG V, BOK R et al.: Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. J. Clin. Oncol. (2003) 21(1):99-105.
   PubMed Web of Science ®Google Scholar
• DREICER R, KLEIN EA, ELSON P et al.: Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate cancer. Urol. Oncol. (2005) 23(2):82-86.
   PubMed Web of Science ®Google Scholar
• SCHWAAB T, TRETTER CP, GIBSON JJ et al.: Tumor-related immunity in prostate cancer patients treated with human recombinant granulocyte monocyte-colony stimulating factor (GM-CSF). Prostate (2006) 66(6):667-674.
   PubMed Web of Science ®Google Scholar
• RINI BI, FONG L, WEINBERG V et al.: Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor. J. Urol. (2006) 175(6):2087-2091.
   PubMed Web of Science ®Google Scholar
• KRUMMEL MF, ALLISON JP: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. (1995) 182(2):459-465.
   PubMed Web of Science ®Google Scholar
• LEACH DR, KRUMMEL MF, ALLISON JP: Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 271(5256):1734-1736.
   PubMed Web of Science ®Google Scholar
• HURWITZ AA, FOSTER BA, KWON ED et al.: Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. (2000) 60(9):2444-2448.
   PubMed Web of Science ®Google Scholar
• GABRILOVICH DI, CHEN HL, GIRGIS KR et al.: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. (1996) 2(10):1096-1103.
   PubMed Web of Science ®Google Scholar
• OHM JE, CARBONE DP: VEGF as a mediator of tumor-associated immunodeficiency. Immunol. Res. (2001) 23(2-3):263-272.
   PubMed Web of Science ®Google Scholar
• LAXMANAN S, ROBERTSON SW, WANG E et al.: Vascular endothelial growth factor impairs the functional ability of dendritic cells through Id pathways. Biochem. Biophys. Res. Commun. (2005) 334(1):193-198.
   PubMed Web of Science ®Google Scholar
• LI B, LALANI AS, HARDING TC et al.: Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin. Cancer Res. (2006) 12(22):6808-6816.
   PubMed Web of Science ®Google Scholar
• MACHIELS JP, REILLY RT, EMENS LA et al.: Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. (2001) 61(9):3689-3697.
   PubMed Web of Science ®Google Scholar
• PRELL RA, GEARIN L, SIMMONS A et al.: The anti-tumor efficacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel administration. Cancer Immunol. Immunother. (2006) 55(10):1285-1293.
   PubMed Web of Science ®Google Scholar
• EMENS LA, MACHIELS JP, REILLY RT et al.: Chemotherapy: friend or foe to cancer vaccines? Curr. Opin. Mol. Ther. (2001) 3(1):77-84.
   PubMed Web of Science ®Google Scholar
• HEGE KM, JOOSS K, PARDOLL D: GM-CSF gene-modifed cancer cell immunotherapies: of mice and men. Int. Rev. Immunol. (2006) 25(5-6):321-352.
   PubMed Web of Science ®Google Scholar
• JAFFEE EM, THOMAS MC, HUANG AY et al.: Enhanced immune priming with spatial distribution of paracrine cytokine vaccines. J. Immunother. Emphasis Tumor Immunol. (1996) 19(3):176-183.
   PubMed Web of Science ®Google Scholar
• SCHEFFER SR, NAVE H, KORANGY F et al.: Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int. J. Cancer (2003) 103(2):205-211.
   PubMed Web of Science ®Google Scholar
• MARKOWICZ S, ENGLEMAN EG: Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. J. Clin. Invest. (1990) 85(3):955-961.
   PubMed Web of Science ®Google Scholar
• CAUX C, DEZUTTER-DAMBUYANT C, SCHMITT D et al.: GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells. Nature (1992) 360(6401):258-261.
   PubMed Web of Science ®Google Scholar
• BORRELLO I, SOTOMAYOR EM, COOKE S et al.: A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines. Hum. Gene Ther. (1999) 10(12):1983-1991.
   PubMed Web of Science ®Google Scholar
• SIMMONS AD, LI B, GONZALEZ-EDICK M et al.: GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of action. Cancer Immunol. Immunother. (2007) 56(10):1653-1665.
   PubMed Web of Science ®Google Scholar
• EAGER R, NEMUNAITIS J: GM-CSF gene-transduced tumor vaccines. Mol. Ther. (2005) 12(1):18-27.
   PubMed Web of Science ®Google Scholar
• SIMONS JW, MIKHAK B, CHANG JF et al.: Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. (1999) 59(20):5160-5168.
   PubMed Web of Science ®Google Scholar
• SIMONS JW, CARDUCCI MA, MIKHAK B et al.: Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin. Cancer Res. (2006) 12(11 Part 1):3394-3401.
   PubMed Web of Science ®Google Scholar
• SMALL EJ, SACKS N, NEMUNAITIS J et al.: Granulocyte macrophage colony-stimulating factor – secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin. Cancer Res. (2007) 13(13):3883-3891.
   PubMed Web of Science ®Google Scholar
• PETRYLAK DP, TANGEN CM, HUSSAIN MH et al.: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. (2004) 351(15):1513-1520.
   PubMed Web of Science ®Google Scholar
• TANNOCK IF, DE WIT R, BERRY WR et al.: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. (2004) 351(15):1502-1512.
   PubMed Web of Science ®Google Scholar
• NIGAM A, YACAVONE RF, ZAHURAK ML et al.: Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines. Int. J. Oncol. (1998) 12(1):161-170.
   PubMed Web of Science ®Google Scholar
• MCNEEL DG: Cellular immunotherapies for prostate cancer. Biomed. Pharmacother. (2007) 61(6):315-322.
   PubMed Web of Science ®Google Scholar
• SMALL EJ, SCHELLHAMMER PF, HIGANO CS et al.: Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. (2006) 24(19):3089-3094.
   PubMed Web of Science ®Google Scholar
• MICHAEL A, BALL G, QUATAN N et al.: Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin. Cancer Res. (2005) 11(12):4469-4478.
   PubMed Web of Science ®Google Scholar
• LEONG SP, ENDERS-ZOHR P, ZHOU YM et al.: Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma. J. Immunother. (1997) (1999) 22(2):166-174.
   PubMed Web of Science ®Google Scholar
• FONG L, KAVANAUGH B, RINI BI et al.: A Phase I trial of combination immunotherapy with CTLA-4 blockade and GM-CSF in hormone-refractory prostate cancer. Proc. Am. Soc. Clin. Oncol. (2006) 24(S102):Abstract 2508.
   Google Scholar
• NEMUNAITIS J, JAHAN T, ROSS H et al.: Phase I/II trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther. (2006) 13(6):555-562.
   PubMed Web of Science ®Google Scholar
• MCNEEL DG, SCHIFFMAN K, DISIS ML: Immunization with recombinant human granulocyte-macrophage colony-stimulating factor as a vaccine adjuvant elicits both a cellular and humoral response to recombinant human granulocyte-macrophage colony-stimulating factor. Blood (1999) 93(8):2653-2659.
   PubMed Web of Science ®Google Scholar
• HARDING TC, NGUYEN MC, KOPRIVNIKAR K et al.: Identification of antibody responses induced in patients with metastatic hormone-refractory prostate cancer (HRPC) treated with a GM-CSF-transduced allogeneic prostate cancer immunotherapy. Proc. Am. Assn. Cancer Res. (2007) 48(981):Abstract 4139.
   Google Scholar
• WEISSMAN RM, COFFEY DS, SCOTT WW: Cell kinetic studies of prostatic cancer: adjuvant therapy in animal models. Oncology (1977) 34(3):133-137.
   PubMed Web of Science ®Google Scholar

Website

• http://seer.cancer.gov/csr/1975_2004/ RIES LAG, MELBERT D, KRAPCHO M et al.: SEER Cancer Statistics Review, 1975 – 2004, National Cancer Institute. Bethesda, MD, based on November 2006 SEER data submission, posted to the SEER website (2007).
   Google Scholar